Can you take Gilteritinib with Glycerin?
1 drug interaction and 7 additional warnings found for the following 2 drugs:
- gilteritinib
- glycerin
Drug interactions
Moderate drug interactions
Moderate:
glycerin gilteritinib
Applies to: glycerin and gilteritinib
Gilteritinib can cause an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect.
The risk is increased if you have:
- a heart condition called congenital long QT syndrome
- other cardiac diseases
- conduction abnormalities
- electrolyte disturbances, such as low blood levels of magnesium or potassium
These electrolyte disturbances can occur with bowel cleansing preparations or excessive use of medications that have a laxative effect, such as glycerin.
Do not exceed the dose and duration recommended on the product label or prescribed by your doctor.
You should seek immediate medical attention if you experience sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications, whether taken together or separately.
In addition, you should let your doctor know if you experience signs and symptoms of low magnesium or potassium blood level such as:
- weakness
- tiredness
- drowsiness
- dizziness
- confusion
- tingling
- numbness
- muscle pain
- cramps
- nausea
- vomiting
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Disease interactions
7 potential interactions Applies to: 7 conditions, including Hypokalemia, Inflammatory Bowel Disease, Liver Disease, Long QT Syndrome, and Renal Dysfunction.
Gastrointestinal Obstruction
Major:
glycerin
Glycerin has a major potential interaction with Gastrointestinal Obstruction.
The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.
Hypokalemia
Moderate:
gilteritinib
Gilteritinib has a moderate potential interaction with Hypokalemia.
Gilteritinib has been associated with prolonged cardiac ventricular repolarization (QT interval). Perform electrocardiogram (ECG) prior to initiation of treatment with gilteritinib, on days 8 and 15 of cycle 1, and prior to the start of the next two subsequent cycles. Interrupt and reduce the dosage of gilteritinib in patients who have a QTcF >500 msec. Hypokalemia or hypomagnesemia may increase the QT prolongation risk. Correct hypokalemia or hypomagnesemia prior to and during treatment administration.
Inflammatory Bowel Disease
Major:
glycerin
Glycerin has a major potential interaction with Inflammatory Bowel Disease.
The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.
Liver Disease
Moderate:
gilteritinib
Gilteritinib has a moderate potential interaction with Liver Disease.
The effect of severe hepatic (Child-Pugh Class C) or severe renal impairment (Clcr = 29 mL/min) on gilteritinib pharmacokinetics is unknown.
Long QT Syndrome
Moderate:
gilteritinib
Gilteritinib has a moderate potential interaction with Long QT Syndrome.
Gilteritinib has been associated with prolonged cardiac ventricular repolarization (QT interval). Perform electrocardiogram (ECG) prior to initiation of treatment with gilteritinib, on days 8 and 15 of cycle 1, and prior to the start of the next two subsequent cycles. Interrupt and reduce the dosage of gilteritinib in patients who have a QTcF >500 msec. Hypokalemia or hypomagnesemia may increase the QT prolongation risk. Correct hypokalemia or hypomagnesemia prior to and during treatment administration.
Magnesium Imbalance
Moderate:
gilteritinib
Gilteritinib has a moderate potential interaction with Magnesium Imbalance.
Gilteritinib has been associated with prolonged cardiac ventricular repolarization (QT interval). Perform electrocardiogram (ECG) prior to initiation of treatment with gilteritinib, on days 8 and 15 of cycle 1, and prior to the start of the next two subsequent cycles. Interrupt and reduce the dosage of gilteritinib in patients who have a QTcF >500 msec. Hypokalemia or hypomagnesemia may increase the QT prolongation risk. Correct hypokalemia or hypomagnesemia prior to and during treatment administration.
Renal Dysfunction
Moderate:
gilteritinib
Gilteritinib has a moderate potential interaction with Renal Dysfunction.
The effect of severe hepatic (Child-Pugh Class C) or severe renal impairment (Clcr = 29 mL/min) on gilteritinib pharmacokinetics is unknown.
Report options
More resources
gilteritinib
A total of 534 drugs are known to interact with gilteritinib.
- Gilteritinib is in the drug class multikinase inhibitors.
- Gilteritinib is used to treat Acute Myeloid Leukemia.
glycerin
A total of 267 drugs are known to interact with glycerin.
- Glycerin is in the drug class laxatives.
- Glycerin is used to treat the following conditions:
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.